Harnessing innate power: Targeting the root causes of inflammation and fibrosis
Our approach is to target upstream innate immune amplifiers that underpin persistent inflammatory and fibrotic responses to restore tissue homeostasis and disrupt disease progression.
At Calluna Pharma we are developing first-in-class therapies designed to defeat chronic inflammation and fibrosis at the source. Our innovative therapeutic approach targets upstream amplifiers of disease offering potential applicability across a diverse array of medical conditions. Calluna Pharma is a clinical stage company driven by a commitment to improve patient outcomes in areas where existing treatments are sub-optimal.
We believe in the power of immunology to push boundaries, challenge the status quo, and develop therapies that will make a real difference for people living with serious diseases.
Neutralizing upstream innate immune amplifiers provides a novel pleiotropic approach.
Therapeutic breakthroughs: Our pipeline
We have four promising therapies in the pipeline, with preclinical proof of concept data.
We bring together a mix of skills and backgrounds, from various academic institutions to different roles in biotech and large pharma companies. Our collective experience helps us navigate the complexities of drug discovery and development, merging strategic thinking with practical know-how and a strong commitment to effective clinical execution.
John Montana PhD
John’s 30 years of diverse R&D experience shapes Calluna Pharma’s innovative edge, blending drug discovery acumen with strong leadership.
Jonas Hallén MD PhD
CMO and Founder
As a co-founder and passionate drug developer, Jonas strongly believes in the power of science to make a meaningful impact on patients’ lives.
With a career spanning pharma and biotech, Louise provides Calluna Pharma with financial leadership, fostering strategic growth and stability.
Our unique therapeutic solutions, targeting sentinel modulators and key self-amplifying alarm signals of the immune system, present an exciting investment opportunity. Noted industry investor Forbion already recognizes Calluna Pharma’s potential and has made a strategic investment, underscoring our credibility and commercial promise.
A partnership with Calluna Pharma brings more than just the potential for financial gains. It’s an opportunity to contribute to improving patient outcomes and elevating therapeutic standards. The combination of our scientific excellence, discovery expertise, and accomplished management team, alongside our robust clinical plans could add considerable credibility to your investment portfolio.
Keep up to date with our recent breakthroughs and partnerships as we endeavour to identify novel life changing treatments for a range of inflammatory and fibrotic diseases.
Calluna Pharma launches and announces EUR 75 million Series A financing to develop novel therapies for inflammatory and fibrotic diseases
Oxitope Pharma (Oxitope) and Arxx Therapeutics (Arxx) announced their merger to form Calluna Pharma Inc.Read more
More news coming soon
More news coming soon
Get in touch
"*" indicates required fields